Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead candidate being CardiolRx, an oral solution of cannabidiol [5][6] - The company is debt-free and well-capitalized to achieve its corporate milestones into 2026 [4] Product Development - CardiolRx has received Orphan Drug Designation from the US FDA for the treatment of pericarditis, including recurrent pericarditis, which affects approximately 38,000 patients annually in the United States [2][3][6] - The MAVERIC Program for recurrent pericarditis includes the Phase II MAvERIC-Pilot study, the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial, with MAVERIC-2 expected to initiate in Q4 2024 [2][6] - Cardiol is also advancing CRD-38, a proprietary subcutaneously administered therapy for heart failure, a leading cause of death and hospitalization in developed countries [4][7] Market Insights - The global pericarditis market was valued at $2.44 billion in 2023 and is projected to grow at a CAGR of 5.24%, reaching $3.87 billion by 2032 [3] - Healthcare costs associated with heart failure in the United States exceed $30 billion annually [7] Industry Recognition - Cardiol Therapeutics has been added to the PRISM Emerging Biotech Index, highlighting its role in innovation and market impact within the biotech sector [1]